Some people use niacin or metformin dose for acne, leprosy, attention deficit-hyperactivity disorder (ADHD), memory loss, arthritis, preventing premenstrual headache, improving digestion, protecting against toxins and pollutants, reducing the effects of aging, lowering blood pressure, improving circulation, promoting relaxation, improving orgasm, and preventing cataracts. Mean changes from baseline in blood pressure at the end of the double-blind treatment for CONCERTA® and placebo-treated patients were -1.2 and -0.5 mm Hg (systolic) and 1.1 and 0.4 mm Hg (diastolic), respectively [see WARNINGS and PRECAUTIONS). Take METFORMIN exactly as prescribed. Make sure laboratory personnel and all your doctors know you use this drug. For example, metformin dose may increase central noradrenergic activity; alternatively, the effect may be attributable to dopaminergic effects (ie, represent akathisia). No evidence of bone marrow cytotoxicity was found in any of the species examined. There was a significant decrease in the mean percentage change in daily “as-needed”inhaled?-agonist use (11.7% decrease from baseline in the group treated with METFORMIN DOSE vs 8.2% increase from baseline in the placebo group, p 0.05). Cases of cough, including positive re-challenges, have been reported with the use of losartan in post-marketing experience. (See CLINICAL STUDIES, Special Studies, Platelets and PRECAUTIONS, Cardiovascular Effects.) Prospective, long-term studies on concomitant administration of VIOXX and metformin have not been conducted. Because of this, when taken alone, they rarely cause hypoglycemia (low blood sugar), and usually do not cause weight gain. The appearance of hypotension after the initial dose of METFORMIN DOSE does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. Patients should be advised not to breast-feed an infant if they are taking RISPERDAL® [see Use in Specific Populations]. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg metformin dose disk should be interpreted according the criteria outlined in Table 11. Insufficient clinical response indicated a worsening of the patient's condition that resulted in study discontinuation, as assessed by the investigator.